Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alflutinib in T790M-positive NSCLC
NCT03452592Phase 2Terminated
- Sponsor
- Allist Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Apr 2018; status: terminated.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03452592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452592.